Explore

Rapid Read Rapid Read
Yellowbird Diagnostics Initiates Phase 1 Trial for NeuCaVis Imaging Agent

Yellowbird Diagnostics Initiates Phase 1 Trial for NeuCaVis Imaging Agent

Yellowbird Diagnostics Inc. has commenced its Phase I clinical trial for NeuCaVis™, a novel metabolic PET imaging agent designed to visualize inflammation with high specificity. The trial, conducted at the University of Ottawa Heart Institute, involves dosing and imaging of healthy volunteers to assess the safety, tolerability, and dosimetry of NeuCaVis™. This imaging agent targets fructose metabolism, a pathway linked to inflammatory activity, and aims to improve the detection of conditions such as cardiovascular diseases, chronic inflammatory disorders, neuroinflammation, and cancer. The trial is expected to conclude in June 2026, marking a significant milestone for Yellowbird in advancing molecular imaging technology.
Trendline Trendline
Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis
Rapid Read Rapid Read
Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease

Bracco, a leader in diagnostic imaging, has expressed strong support for the American Society of Nuclear Cardiology's (ASNC) recent position statement. The ASNC recommends cardiac positron emission tomography (PET) with myocardial blood flow quantification as the preferred method for evaluating coronary artery disease (CAD). This endorsement is based on clinical evidence suggesting that cardiac PET offers superior diagnostic accuracy and risk assessment compared to SPECT imaging. Bracco has been a pioneer in this field since 1989, promoting the adoption of cardiac PET by improving access, reimbursement, and clinical education.
Trendline Trendline
Yellowbird Diagnostics Initiates Phase 1 Trial of NeuCaVis for Inflammation Imaging

Yellowbird Diagnostics Initiates Phase 1 Trial of NeuCaVis for Inflammation Imaging

Yellowbird Diagnostics Initiates Phase 1 Trial of NeuCaVis for Inflammation Imaging
Trendline Trendline
Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach
Trendline Trendline
Co-Diagnostics to Present PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present PCR Platform at ESCMID 2026, Aiming to Expand Global Reach
Trendline Trendline
Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test

Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test

Beckman Coulter Diagnostics Introduces Rapid Bacterial vs. Viral Infection Test
Rapid Read Rapid Read
QIAGEN Launches Rapid Syndromic Testing Panel for Bloodstream Infections

QIAGEN Launches Rapid Syndromic Testing Panel for Bloodstream Infections

QIAGEN N.V. has announced the launch of its CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, expanding its syndromic testing capabilities to include bloodstream infections. This new panel can identify 20 gram-positive bacterial and fungal pathogen targets and 10 antimicrobial resistance markers from positive blood cultures and colonies in about one hour. The launch coincides with the ESCMID Global 2026 Congress, where QIAGEN will showcase its infectious disease portfolio. The rapid identification of pathogens and resistance markers is crucial for timely treatment decisions in bloodstream infections, supporting laboratory workflows and patient management.
Trendline Trendline
Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation

Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation

Beckman Coulter Diagnostics Introduces Rapid Assay for Infection Differentiation
Trendline Trendline
Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream
Trendline Trendline
Johnson Johnson Exceeds Q1 2026 Earnings Expectations with Oncology and MedTech Growth

Johnson Johnson Exceeds Q1 2026 Earnings Expectations with Oncology and MedTech Growth

Johnson Johnson Exceeds Q1 2026 Earnings Expectations with Oncology and MedTech Growth
Trendline Trendline
FDA Grants Clearance to Protaryx Medical for Innovative Transseptal Puncture Device

FDA Grants Clearance to Protaryx Medical for Innovative Transseptal Puncture Device

FDA Grants Clearance to Protaryx Medical for Innovative Transseptal Puncture Device